Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.

Abstract excerpt

BACKGROUND: Etamicastat is a new dopamine-β-hydroxylase (DβH) inhibitor currently in clinical development for the treatment of hypertension and heart failure. OBJECTIVES: To evaluate the pharmacokinetics and tolerability of etamicastat after single and repeated administration in elderly subjects (aged ≥65 years) relative to young adult healthy controls (aged 18-45 years). METHODS: This was a single-center,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Area Under Curve
• Share to Arylamine N-Acetyltransferase